Cargando…

Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis

BACKGROUND AND OBJECTIVE: Bioimpedance technologies are increasingly used to determine fluid status in patients with chronic kidney disease and those with end-stage kidney disease on dialysis. We aimed to determine whether this technology improves clinical outcomes as compared with usual care. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Horowitz, Laura, Karadjian, Oliver, Braam, Branko, Mavrakanas, Thomas, Weber, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338662/
https://www.ncbi.nlm.nih.gov/pubmed/37457623
http://dx.doi.org/10.1177/20543581231185433
_version_ 1785071673936969728
author Horowitz, Laura
Karadjian, Oliver
Braam, Branko
Mavrakanas, Thomas
Weber, Catherine
author_facet Horowitz, Laura
Karadjian, Oliver
Braam, Branko
Mavrakanas, Thomas
Weber, Catherine
author_sort Horowitz, Laura
collection PubMed
description BACKGROUND AND OBJECTIVE: Bioimpedance technologies are increasingly used to determine fluid status in patients with chronic kidney disease and those with end-stage kidney disease on dialysis. We aimed to determine whether this technology improves clinical outcomes as compared with usual care. METHODS: We performed a systematic review and meta-analysis of trials, comparing fluid management guided by bioimpedance technologies to standard of care in patients with chronic kidney disease. Our primary outcome was all-cause mortality. Secondary outcomes included blood pressure control, all-cause hospitalization, major adverse cardiovascular events, and change in left ventricular mass index. RESULTS: Our search identified 819 citations of which 12 randomized controlled trials were included (2420 patients). No studies of non-dialysis-dependent chronic kidney disease patients met inclusion criteria. Mean age was 55 years and mean follow-up was 1 year. There was a statistically significant difference in all-cause mortality between both arms studied (risk ratio [RR] 0.64, 95% confidence interval [CI]: 0.44, 0.99). Better blood pressure control was observed in the bioimpedance arm of the included articles, weighted mean differences (WMD) −3.13 mm Hg (95% CI: −5.73, −0.53 mm Hg) for systolic blood pressure and WMD −2.50 mm Hg (95% CI: −4.36, −0.64 mm Hg) for diastolic blood pressure. No difference was observed concerning the other outcomes. CONCLUSIONS: Among patients on maintenance dialysis, bioimpedance-guided volume management showed decreased all-cause mortality and blood pressure but no significant difference in all-cause hospitalization, major adverse cardiac event, or change in left ventricular mass index. This may be due to a younger population sample than previous articles. Moreover, our study identified a knowledge gap by highlighting the lack of studies evaluating this technology in non-dialysis-dependent chronic kidney disease patients.
format Online
Article
Text
id pubmed-10338662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103386622023-07-14 Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis Horowitz, Laura Karadjian, Oliver Braam, Branko Mavrakanas, Thomas Weber, Catherine Can J Kidney Health Dis Original Clinical Research Quantitative BACKGROUND AND OBJECTIVE: Bioimpedance technologies are increasingly used to determine fluid status in patients with chronic kidney disease and those with end-stage kidney disease on dialysis. We aimed to determine whether this technology improves clinical outcomes as compared with usual care. METHODS: We performed a systematic review and meta-analysis of trials, comparing fluid management guided by bioimpedance technologies to standard of care in patients with chronic kidney disease. Our primary outcome was all-cause mortality. Secondary outcomes included blood pressure control, all-cause hospitalization, major adverse cardiovascular events, and change in left ventricular mass index. RESULTS: Our search identified 819 citations of which 12 randomized controlled trials were included (2420 patients). No studies of non-dialysis-dependent chronic kidney disease patients met inclusion criteria. Mean age was 55 years and mean follow-up was 1 year. There was a statistically significant difference in all-cause mortality between both arms studied (risk ratio [RR] 0.64, 95% confidence interval [CI]: 0.44, 0.99). Better blood pressure control was observed in the bioimpedance arm of the included articles, weighted mean differences (WMD) −3.13 mm Hg (95% CI: −5.73, −0.53 mm Hg) for systolic blood pressure and WMD −2.50 mm Hg (95% CI: −4.36, −0.64 mm Hg) for diastolic blood pressure. No difference was observed concerning the other outcomes. CONCLUSIONS: Among patients on maintenance dialysis, bioimpedance-guided volume management showed decreased all-cause mortality and blood pressure but no significant difference in all-cause hospitalization, major adverse cardiac event, or change in left ventricular mass index. This may be due to a younger population sample than previous articles. Moreover, our study identified a knowledge gap by highlighting the lack of studies evaluating this technology in non-dialysis-dependent chronic kidney disease patients. SAGE Publications 2023-07-11 /pmc/articles/PMC10338662/ /pubmed/37457623 http://dx.doi.org/10.1177/20543581231185433 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Clinical Research Quantitative
Horowitz, Laura
Karadjian, Oliver
Braam, Branko
Mavrakanas, Thomas
Weber, Catherine
Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis
title Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis
title_full Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis
title_fullStr Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis
title_full_unstemmed Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis
title_short Bioimpedance-Guided Monitoring of Volume Status in Patients With Kidney Disease: A Systematic Review and Meta-Analysis
title_sort bioimpedance-guided monitoring of volume status in patients with kidney disease: a systematic review and meta-analysis
topic Original Clinical Research Quantitative
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338662/
https://www.ncbi.nlm.nih.gov/pubmed/37457623
http://dx.doi.org/10.1177/20543581231185433
work_keys_str_mv AT horowitzlaura bioimpedanceguidedmonitoringofvolumestatusinpatientswithkidneydiseaseasystematicreviewandmetaanalysis
AT karadjianoliver bioimpedanceguidedmonitoringofvolumestatusinpatientswithkidneydiseaseasystematicreviewandmetaanalysis
AT braambranko bioimpedanceguidedmonitoringofvolumestatusinpatientswithkidneydiseaseasystematicreviewandmetaanalysis
AT mavrakanasthomas bioimpedanceguidedmonitoringofvolumestatusinpatientswithkidneydiseaseasystematicreviewandmetaanalysis
AT webercatherine bioimpedanceguidedmonitoringofvolumestatusinpatientswithkidneydiseaseasystematicreviewandmetaanalysis